Success Metrics

Clinical Success Rate
42.9%

Based on 3 completed trials

Completion Rate
43%(3/7)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
4(57%)

Phase Distribution

Ph phase_2
4
57%
Ph phase_1
3
43%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

42.9%

3 of 7 finished

Non-Completion Rate

57.1%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(3)
Terminated(4)

Detailed Status

Terminated4
Completed3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
42.9%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 24 (57.1%)

Trials by Status

completed343%
terminated457%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_2

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

NCT03531827
terminatedphase_1

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

NCT02010567
completedphase_2

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

NCT02187302
completedphase_2

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

NCT01380769
terminatedphase_1

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

NCT02648711
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03531827Phase 2

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Terminated
NCT02010567Phase 1

Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer

Terminated
NCT02187302Phase 2

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Completed
NCT01380769Phase 2

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Completed
NCT02648711Phase 1

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Terminated
NCT02389985Phase 1

A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Terminated
NCT01652079Phase 2

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7